Cancer Immunotherapy at FDA's Door as West Nile Breaks European Records

Today's roundup covers two FDA oncology decisions arriving this week, Europe's most severe West Nile virus season on record, a new cholera outbreak in sub-Saharan Africa, and a landmark study that brings 2.5 million children's health records to bear on one of public health's most debated questions.

Monday, 5 October: FDA Decision Imminent for Immunotherapy in Stage III Colon Cancer

For roughly 15 percent of newly diagnosed colon cancer cases — those whose tumours carry a fault in DNA mismatch repair (dMMR) — adjuvant chemotherapy after surgery has historically offered only modest protection against recurrence. Results from the phase 3 ATOMIC trial, run by the Alliance for Clinical Trials in Oncology, change that calculation. The study enrolled patients with resected stage III dMMR colon cancer and randomly assigned them to modified FOLFOX-6 chemotherapy alone or FOLFOX-6 plus atezolizumab, a PD-L1 checkpoint inhibitor marketed as Tecentriq by Roche/Genentech. Adding atezolizumab reduced the risk of disease recurrence or death by 50 percent compared with chemotherapy alone. Three-year disease-free survival was 86 percent in the combination arm versus 76 percent with chemotherapy alone, over a median follow-up of nearly 41 months.

The FDA accepted Genentech's supplemental biologics licence application in June 2026 with Priority Review status, setting a target action date of 9 October 2026. If cleared, atezolizumab would be the first immunotherapy approved as adjuvant therapy in stage III colon cancer — a disease affecting an estimated 50,000 new patients annually in the United States. The ATOMIC result is a confirmed phase 3 finding; this week's PDUFA decision is the remaining regulatory step.

Monday, 5 October: First B7-H3-Directed Therapy Reaches FDA Decision Gate for Lung Cancer

Small cell lung cancer remains one of oncology's most difficult diseases to treat: more than 95 percent of patients have extensive-stage disease at diagnosis, and median overall survival with current first-line regimens is measured in months. Ifinatamab deruxtecan — a novel antibody-drug conjugate (ADC) that targets B7-H3, a protein expressed on the surface of more than 90 percent of small cell lung cancer specimens — has received FDA Priority Review, with a PDUFA date of 10 October 2026.

ADCs work by attaching a tumour-targeting antibody to a potent cytotoxic payload, delivering chemotherapy directly into cancer cells while limiting exposure to surrounding healthy tissue. B7-H3 is also expressed broadly in other solid tumour types, meaning a positive FDA decision on ifinatamab deruxtecan would open the door for this target class across multiple future indications. The drug is being developed by a collaboration between Daiichi Sankyo and MSD (Merck). A regulatory decision is expected on Friday, 10 October.

Monday, 5 October: West Nile Virus Posts Europe's Worst Season on Record — Greece and Italy at Epicentre

Europe's 2026 West Nile virus transmission season has become the continent's most severe since systematic surveillance began. As of late September, the ECDC and EFSA joint surveillance report documented 1,285 locally acquired human cases across 15 EU member states — a nearly 50-percent increase over the same period in 2025. Italy reported the highest case count (590), followed by Greece (319), Spain (104), and Romania (77). Twelve deaths have been confirmed: six in Greece, five in Italy, and one in Romania.

The virus circulates through a mosquito–bird cycle: Culex mosquitoes acquire the pathogen from infected migratory birds travelling along the Africa–Middle East–Europe flyway, then transmit it to humans incidentally. WHO Europe attributes the escalating season to warmer autumns that sustain mosquito activity beyond historical norms — an effect projected to intensify as Mediterranean temperatures continue to rise.

For Cyprus and the wider eastern Mediterranean, which sits directly beneath major migratory bird corridors, the ECDC recommends maintaining active arboviral surveillance through November. Residents in agricultural and wetland areas are advised to use insect repellent and avoid outdoor exposure at dawn and dusk. No licensed human vaccine or specific antiviral therapy for West Nile virus exists; management remains supportive. Most infections (approximately 80 percent) cause no symptoms; around one in 150 cases progresses to neuroinvasive disease, which can include encephalitis, meningitis, or acute flaccid paralysis.

Monday, 5 October: Zambia Declares New Cholera Outbreak

Zambia's Ministry of Health declared a cholera outbreak on 30 September 2026. WHO figures show 304 reported cases — 62 laboratory-confirmed — and 11 deaths as of 29 September, a case fatality rate of approximately 3.6 percent. WHO's threshold for heightened response is a CFR above 1 percent in the alert phase, triggering accelerated water, sanitation, and oral rehydration interventions. WHO and UNICEF deployed field teams to affected districts in early October to establish oral rehydration points, support water chlorination, and begin an oral cholera vaccine (OCV) campaign.

Cholera spreads through water or food contaminated with the bacterium Vibrio cholerae. Sub-Saharan Africa has experienced a series of unusually severe outbreaks since 2022, linked to inadequate water infrastructure, population displacement, and climate-related flooding that disrupts sanitation systems. This is Zambia's fourth cholera outbreak since 2022. Oral cholera vaccines, given in two doses, offer 60–85 percent protection for up to three years and are a key component of WHO's global cholera control roadmap alongside sustainable improvements in water and sanitation.

Monday, 5 October: The Largest US Study of Its Kind Finds No MMR–Autism Link

A study drawing on the electronic health records of more than 2.5 million children has found no statistical association between receiving the measles-mumps-rubella (MMR) vaccine before age two and a subsequent autism spectrum disorder diagnosis. The research, published in The Pediatric Infectious Disease Journal in October 2026, was led by Todd L. Burstain of UW Medicine. The team used an age-anchored landmark analysis — a method that compares vaccinated and unvaccinated children at identical developmental milestones, avoiding the bias introduced when autism is commonly diagnosed at the same ages that MMR vaccination typically occurs.

Children who received their first MMR dose between 11.5 and 24 months of age were no more likely to receive an autism diagnosis than same-age peers who had not yet been vaccinated. The dataset was drawn from the COSMOS electronic health record network and covers records from January 2015 through December 2024 — the largest US-based investigation of this question to date.

The result extends a consistent body of international evidence: large studies in Denmark (650,000 children), Japan, the United Kingdom, and elsewhere have each reached the same conclusion over the past two decades. The hypothesis that MMR causes autism originated in a 1998 paper that was fully retracted in 2010 after investigators found the underlying data had been manipulated; its author subsequently lost his medical licence. The new US study provides further empirical grounding for clinicians advising families who continue to have questions about MMR timing.

---

The content above is journalistic in nature and is not a substitute for professional medical advice, diagnosis, or treatment. Readers should consult a qualified clinician or pharmacist before making any change to their medication, vaccination schedule, or healthcare routine.